Novel K540N mutation in Plasmodium falciparum dihydropteroate synthetase confers a lower level of sulfa drug resistance than does a K540E mutation

Antimicrob Agents Chemother. 2011 May;55(5):2481-2. doi: 10.1128/AAC.01394-10. Epub 2011 Feb 22.

Abstract

Sulfadoxine (SDX) and sulfamethoxazole (SMX) each inhibit the Plasmodium falciparum dihydropteroate synthetase (PfDHPS), and certain point mutations in this enzyme yield the drug-resistant parasite. Using a simple Escherichia coli model system, we describe here the effect of the recently reported novel K540N mutation in PfDHPS on the level of SDX/SMX resistance. The survival rate of the transformed E. coli (DHPS-deficient strain) under different SDX or SMX concentrations revealed that the K540N mutation confers a lower level of drug resistance than its contemporary K540E mutation. Further, SMX was more effective than SDX in the E. coli system.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimalarials / pharmacology*
  • Dihydropteroate Synthase / genetics*
  • Drug Resistance / genetics
  • Inhibitory Concentration 50
  • Mutation
  • Plasmodium falciparum / drug effects*
  • Plasmodium falciparum / enzymology*
  • Plasmodium falciparum / genetics
  • Sulfadoxine / pharmacology*
  • Sulfamethoxazole / pharmacology*

Substances

  • Antimalarials
  • Sulfadoxine
  • Dihydropteroate Synthase
  • Sulfamethoxazole